Digital Edition: Vol. 7, No. 2 - February 5, 2020 - MedTech Strategist

article image
ARTICLE SUMMARY:

Liquid biopsy play Thrive Earlier Detection launched last year with a $110 million Series A, the largest initial round for a diagnostics company since Verily’s $800 million haul in 2017. Thrive boasts groundbreaking science and a top-tier executive team, but the start-up faces many challenges in bringing its multi-cancer screening test for asymptomatic patients into primary care. We also cover PQ Bypass’ PAD solution and new investment portal Bioverge.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: